This pharmaceutical company has settled the global biological medicine R & D center in Shanghai, further expanding the enabling platform

[industry trends of China Pharmaceutical network] on November 22, Yaoming biology announced the official opening of the global innovative bio pharmaceutical R & D and pharmaceutical integration center in Fengxian, Shanghai It is reported that the planning building area of the center is 150000 square meters Its design and construction will conform to the cGMP international advanced standards, and make full use of the concept of modularization and flexible activation to organically integrate the discovery, development, clinical and commercial production of biological drugs After completion, the center will become one of the world's largest biomedical R & D and pharmaceutical centers, which can accommodate more than 3000 scientists The author understands that since this year, Yaoming biology has accelerated its actions in broadening the enabling platform On May 16 this year, Yaoming biology announced that it was preparing to build an integrated R & D and production center for biological drugs in Shijiazhuang high tech Zone, Hebei Province It is expected that the first phase of the project will be put into operation in 2020 It is reported that the production center will be composed of a process development laboratory, a clinical sample production base with a capacity of 5000 liters and a commercial production base with a capacity of 48000 liters The design and construction will meet the cGMP standards of the United States, the European Union and China Compared with chemical drugs, biopharmaceutical R & D has high technical threshold and complex production process Whether it is innovation or imitation, the cost and risk of R & D are higher, but the market brought by biopharmaceutical is very large At present, many pharmaceutical companies around the world are strengthening investment in research and development of biological drugs, and creating research and development centers for biological drugs At the same time, there are many foreign large-scale pharmaceutical enterprises that invest the R & D center in all parts of China Suzhou on June 13, 2017, Yasheng pharmaceutical, which focuses on the research and development of small molecule targeted anti-tumor innovative drugs, settled its global research and development center in Suzhou biomedical industrial park, and held the opening ceremony in Suzhou Industrial Park After the global R & D center of Yasheng pharmaceutical settled in the park, the company's research ability in the design and R & D of new target original new drugs, the research of translational medicine and the development of preparations will be continuously improved The industrialization base to be built will provide strong support for the global phase III clinical drug use and the global market drug supply after going to the market It is reported that in recent years, Suzhou Industrial Park has implemented the strategy of transformation and upgrading, innovation driven, and vigorously promoted the development of strategic emerging industries Emerging industries such as biomedicine have maintained an average annual growth of about 30% Wuxi on November 27, 2017, AstraZeneca, a well-known pharmaceutical enterprise, and SDIC Innovation Investment Management Co., Ltd jointly built a global innovative biomedical R & D center in Wuxi high tech Industrial Development Zone to jointly promote new drug R & D in China It is understood that this is the first cooperation project between the world's top 500 multinational pharmaceutical enterprises and local funds to carry out new drug research and development, and also the first Sino foreign joint venture type 1.1 innovative drug research and development project in the world At present, AstraZeneca China Innovation Center has performed well in drug research and development The cooperation between the two sides will help to promote the scientific research strength, technical assets of AstraZeneca and the expertise and funds of CIC innovation, and further promote innovation in the field of medical science and technology It is reported that in recent years, Wuxi attaches great importance to the biomedical industry and lists it as one of the emerging development strategies At present, well-known biomedical enterprises such as AstraZeneca, Wuxi Pharma, Pfizer and Huarui have settled in Wuxi As early as 2015, Pfizer, a well-known biopharmaceutical enterprise, established a global Biotechnology Center in Xiasha It is understood that in the 1980s, Pfizer entered the Chinese market and established 4 pharmaceutical factories, as well as Shanghai R & D center and Wuhan R & D center The global Biotechnology Center project is Pfizer's third R & D center in China   It is reported that at present, Hangzhou Economic and Technological Development Zone has gathered 100 biomedical enterprises, including biopharmaceuticals represented by Jiuyuan gene and Aibo biology, chemical pharmaceuticals represented by mosadong and Abbott, medical equipment enterprises represented by telmao, xuhuacheng and Smith, modern Chinese medicine represented by Kanglaite pharmaceutical and Aisheng pharmaceutical 。 In addition to the above regions, there are also many regions with R & D centers for pharmaceutical enterprises Experts said that China's good new drug research and development environment and policies attract foreign pharmaceutical companies The author also believes that these new innovative R & D centers will speed up the promotion of indigenous innovative drugs to the world, benefit more patients and reduce drug prices in the future.